Humacyte (NASDAQ:HUMA) Stock Rating Reaffirmed by Cantor Fitzgerald

Humacyte (NASDAQ:HUMA)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a note issued to investors on Friday, Benzinga reports. They presently have a $13.00 price target on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 150.00% from the company’s current price.

Several other research analysts have also commented on the stock. Benchmark restated a “buy” rating and set a $15.00 price target on shares of Humacyte in a research note on Thursday, September 5th. BTIG Research raised their target price on Humacyte from $8.00 to $11.00 and gave the company a “buy” rating in a report on Monday, July 15th. Finally, EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Humacyte currently has an average rating of “Buy” and an average price target of $9.80.

Humacyte Stock Performance

Shares of NASDAQ HUMA opened at $5.20 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 5.41 and a quick ratio of 5.41. Humacyte has a one year low of $1.96 and a one year high of $9.97. The business’s 50-day moving average price is $6.85 and its two-hundred day moving average price is $5.60. The company has a market capitalization of $619.24 million, a P/E ratio of -5.20 and a beta of 1.47.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Analysts anticipate that Humacyte will post -1.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Humacyte news, Director Brady W. Dougan sold 252,676 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the completion of the sale, the director now directly owns 4,306,464 shares in the company, valued at $28,896,373.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of Humacyte stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $6.35, for a total value of $2,235,911.20. Following the transaction, the director now directly owns 3,677,262 shares of the company’s stock, valued at approximately $23,350,613.70. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Brady W. Dougan sold 252,676 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total value of $1,695,455.96. Following the completion of the sale, the director now directly owns 4,306,464 shares of the company’s stock, valued at $28,896,373.44. The disclosure for this sale can be found here. Insiders sold a total of 1,084,153 shares of company stock valued at $6,869,996 in the last quarter. Insiders own 23.10% of the company’s stock.

Hedge Funds Weigh In On Humacyte

Several large investors have recently bought and sold shares of HUMA. The Manufacturers Life Insurance Company grew its position in Humacyte by 32.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock worth $168,000 after purchasing an additional 8,557 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after buying an additional 1,334,641 shares during the period. Deerfield Management Company L.P. Series C acquired a new stake in Humacyte during the second quarter worth about $1,550,000. AQR Capital Management LLC increased its stake in Humacyte by 1,018.4% during the second quarter. AQR Capital Management LLC now owns 256,342 shares of the company’s stock valued at $1,230,000 after acquiring an additional 233,422 shares during the period. Finally, Marshall Wace LLP raised its holdings in Humacyte by 3,301.5% in the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock valued at $2,226,000 after acquiring an additional 450,031 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.